Gene therapy stocks slammed after scientist reveals safety concerns

Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from a scientific advisory board.

Gene therapy researcher James Wilson, a giant in the field, quit Solid Biosciences Inc.’s advisory board ahead of the company’s initial public offering which was completed last week, because of the possible risks of high systemic dosing of AAV, the company’s delivery system for its cell therapy, according to the company’s IPO prospectus.

Just hours before Solid Biosciences SLDB, -5.06% priced its IPO, it revealed that the U.S.

>>> Original Source <<<